Astellas invests $50m in Poseida’s CAR-T cell therapy
As part of the agreement, Astellas will have exclusive negotiation and first refusal for licencing P-MUC1C-ALLO1 in solid tumours.
As part of the agreement, Astellas will have exclusive negotiation and first refusal for licencing P-MUC1C-ALLO1 in solid tumours.
What's Your Reaction?
